Therapeutics
This section features DDW articles around therapeutics.
Page 1 to 16 of 111 |     NEXT PAGE >
Immunotherapy - Knocking Out Cancer With a One-Two Punch By Dr Mark Chao, et al. Spring 2019
New immunotherapies that integrate innate and adaptive immune responses may increase efficacy against many cancers, and have the potential to expand the range of tumours and patients that can be treated with immunotherapy.

Read More

From Genotype to Phenotype: Leveraging functional genomics in oncology By Dr Menelas Pangalos & Steve Rees et al. Spring 2019
A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine.

Read More

Systems Pharmacology: When multi-targeting is advantageous By Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor Winter 2018/19
The safety and efficacy of therapeutic drugs still requires improvement. In part this is due to the promiscuity of individual drugs, which on average can interact with an estimated 6-28 other off-target moieties.

Read More

The Evolution of Transdermal Drug Delivery and Treating Migraine By Dr Mahmoud Ameri and Hayley Lewis Winter 2018/19
Transdermal Drug Delivery (TDD) is a promising method for drug application that has major advantages over some of the most common routes of drug administration.

Read More

Current Trends in RNA Therapeutics Development By Dr Xiaoqiu Wu and Dr Andrew P. Turnbull Fall 2018
Cellular RNAs play crucial roles during disease progression and represent a diverse and largely untapped class of biomolecules that can be exploited for drug development.

Read More

Therapeutics Discovery at MD Anderson - Making Patients a Priority During Drug Development By Dr Phil Jones Fall 2018
The mission at The University of Texas MD Anderson Cancer Center is to eradicate cancer, which remains a major cause of mortality worldwide. It is the second leading cause of death in the United States and globally, claiming more lives than malaria, HIV/AIDs and tuberculosis combined (or ~1 of every 7 deaths) (1-3).

Read More

Hepatic Model Helps to Predict Clinically-Relevant Botanical-Drug Interactions By Dr Amy L. Roe and Dr Jonathan P. Jackson Fall 2018
Use of botanical-based dietary supplements is increasing among people of all ages and in most geographies. Most of these populations have ready access to conventional medications, with significant polypharmacy observed in older adults.

Read More

Antibiotics & Antimicrobial Resistance (AMR) - A Global Perspective Professor Anthony Coates and Dr Yanmin Hu Summer 2018
Antibiotic resistance is at a crossroad. In the world today, deaths in low income countries from Antimicrobial Resistance (AMR) are predicted to rise dramatically by 2050.

Read More

Analytical Biophysical Tools To Accelerate Discovery of Therapeutic Antibodies By Dr Yasmina Noubia Abdiche Summer 2018
The innate ability of antibodies to bind their targets with high affinity and exquisite specificity is leveraged in the discovery of therapeutic antibodies to treat a broad range of diseases including cancer, autoimmune disease and heart disease.

Read More

Cell Therapy - Preserving Cell Integrity and Viability To Drive Discovery Mary Kay Bates Summer 2018
Cell therapy is poised to play a pivotal role in the development of precision and personalised medicines that will transform healthcare for millions of patients worldwide.

Read More

Bringing Immuno-Oncology Together: How An Immunologist & Oncologist Collaborate By Dr Julia Schuler and Dr Louise Brackenbury Spring 2018
For many years, immunology and oncology operated as separate disciplines within drug discovery. However, recent advances in immuno-oncology (IO) have demonstrated what can be achieved when the two disciplines join forces in developing novel treatments for patients.

Read More

Natural Killer Cells - How NK Cell Therapy Will Transform Immunotherapy By Dr Azusa Tanaka and Dr Michael Seiler Spring 2018
Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours – a major shift in oncology treatment and the battle against cancer.

Read More

Therapeutic Antibodies - New tools to enhance the antibody drug pipeline By Dr Robert Ford & Dr Toni Hoffmann Winter 2017/18
Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development.

Read More

Nanoparticles & Nanomedicines - Exploring The Past, Present and Future By Professor Yvonne Perrie & Dr Euan Ramsay Fall 2017
Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines.

Read More

Oral Peptide Therapeutics - A Holy Grail or Quixotic Quest? By Dr Paul Shields Fall 2017
Technologies have been honed to overcome many of the challenges of administering peptide therapeutics orally, but obstacles remain before drug developers can fully realise the vast potential.

Read More

Tackling Multi-Drug Resistant Bacteria By Dr Ankit Mahadevia Summer 2017
Antibiotic resistance never should have become the public health crisis we are seeing today. As a society, we thought the problem of bacterial infections had been solved decades ago when more than 200 powerful antibiotics representing different classes such as beta-lactam, tetracyclines and macrolides were developed.

Read More

Therapeutics
Page 1 to 16 of 111 |     NEXT PAGE >